Liver Cancer
Conditions
Interventions
NanoICG Group:Interventional embolization with pure drug nano ICG lipiodol suspension
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. The age of patients is 18-60 years old, and the life expectancy is >= 3 months; 2. Patients with primary hepatocellular carcinoma confirmed by histology or cytology or meeting the clinical diagnostic criteria (basic chronic liver disease, typical imaging features, AFP changes) of the code for the diagnosis and treatment of primary liver cancer (2019 Edition) issued by the Health Commission; 3. BCLC stage is stage B or C (surgical resection or surgical resection with large injury, liver transplantation and local ablation are not suitable); 4. Single or multiple lesions in the liver are located in the half liver or limited to the adjacent three liver lobes; 5. The primary branch of portal vein of at least one leaf is unobstructed; 6. The liver function is child-a or child-b before surgical resection, and can reach child-a after liver protection, nutritional rehydration and other treatment; 7. Eastern United States cancer cooperation group status score (ECoG PS) = white blood cell count >= 3.0*10^9/L, 350*10^9/L >= platelet count >= 50*10^9/L, Prothrombin time (PT) shall not exceed the upper limit of normal control for 3 seconds; Serum creatinine was less than 1.5 times of the upper limit of normal; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were less than 3 times of the upper limit of normal; 9. Inform the patients of the possible advantages and disadvantages before and after the operation in detail, and the patients and their families voluntarily choose the treatment plan and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Recurrent liver cancer or previous treatment of liver cancer or portal vein tumor thrombus (including surgery, external radiotherapy, molecular targeted drugs, local ablation, Tai / Tae / TACE, etc.) 2. The tumor thrombus extends into the superior mesenteric vein and/or splenic vein; And patients with hepatic vein, hepatic segment inferior vena cava tumor thrombus or extrahepatic metastasis; 3. Patients with other malignant tumors; 4. Serious heart, lung, kidney, brain, and other important organ diseases; 5. Contraindications of TAE: diffuse liver cancer or tumor volume accounting for 70% or more of the whole liver, intractable massive ascites, intrahepatic high flow arteriovenous shunt; Total bilirubin > 51umol / L and/or albumin < 28g / L, which can not be improved after symptomatic treatment; Combined with active infection, especially bile duct inflammation; Female patients are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate;Operation time;Bleeding volume;Time of clamping porta hepatis;Progression-free survival; | — |
Countries
China
Contacts
Public ContactJingdong Li
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed